Theravance Biopharma, Inc. Payments for Repurchase of Common Stock
Shares the company repurchased and the cash it paid, as filed in its 10-Q and 10-K XBRL (statement of shareholders' equity and cash flow statement).
- Theravance Biopharma, Inc. payments for repurchase of common stock for the quarter ending 2024-12-31 was $0.00, a 100.00% decline year-over-year.
- Theravance Biopharma, Inc. payments for repurchase of common stock for the quarter ending 2024-09-30 was $0.00, a 100.00% decline year-over-year.
- Theravance Biopharma, Inc. payments for repurchase of common stock for the quarter ending 2024-06-30 was $0.00, a 100.00% decline year-over-year.
- Theravance Biopharma, Inc. payments for repurchase of common stock for the quarter ending 2024-03-31 was $445.00K, a 99.20% decline year-over-year.
- Theravance Biopharma, Inc. payments for repurchase of common stock for fiscal 2024 was $445.00K, a 99.77% decline from fiscal 2023.
- Theravance Biopharma, Inc. payments for repurchase of common stock for fiscal 2023 was $197.05M, a 52.95% increase from fiscal 2022.
- Theravance Biopharma, Inc. payments for repurchase of common stock for fiscal 2022 was $128.83M.
| Period end | Payments for Repurchase of Common Stock 3 month | Payments for Repurchase of Common Stock 12 month |
|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $445.00K 10-K · filed 2026-03-23 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $30.71M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $61.60M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $445.00K 10-Q · filed 2025-05-12 | $142.14M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $30.26M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-07 | $197.05M 10-K · filed 2025-03-07 |
| 2023-09-30 | $30.89M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $201.58M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $80.54M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | |
| 2023-03-31 | $55.35M 10-Q · filed 2024-05-15 | |
| 2022-12-31 | $34.79M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-01 | $128.83M 10-K · filed 2024-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |